-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
-
-
-
-
-
-
-
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
-
-
-
-
-
-
-
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
15,734 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

